BioSpace News Archive

Cidara Therapeutics, Inc. presented preclinical data on a CD73-targeting drug-Fc conjugate (DFC) candidate, CBO-212, from the Company’s Cloudbreak ® platform, at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT) in Paris, March 6-8, 2023.

Intelligent Bio Solutions Inc. today announced that it is commencing an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock.

ZTALMY ® U.S. net product revenue of $2.3 million for the fourth quarter of 2022 and $2.9 million for the fiscal year ended December 31, 2022.

IBSA Pharma announced that it has entered into an agreement with Mark Cuban Cost Plus Drug Company, PBC to offer Tirosint® oral capsules at a low cash price via the Cost Plus Drugs online pharmacy.

A study at Hospital for Special Surgery (HSS) found that intraoperative three-dimensional (3D) imaging was superior to two-dimensional radiographs in confirming the accuracy of pedicle screw placement during spine surgery.

X-Bolt has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Pro-X1 will be X-Bolt’s flagship launch in the United States.

Genixus announced it is finalizing the buildout of a new manufacturing site in Concord, N.C., complete with automated manufacturing and cutting edge technology to support the KinetiX syringe platform and expanding portfolio.

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2022, and provided an update on business progress.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported fourth quarter and full year 2022 financial results.

The U.S. Food and Drug Administration has accepted, for review, the supplemental Biologics License Application for Dupixent® to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria that is not adequately controlled with the current standard of care, H1 antihistamine treatment.